“…one team found that almost two years after infection, long COVID patients had not yet cleared the virus from their gut tissue. These persistent viral reservoirs appear to leak spike protein — the part of the virus that gives coronaviruses their distinctive ‘crown’ appearance — into blood circulation, potentially driving inflammation of the brain and other organs, and increasing health consequences such as heart disease.

While early efforts are underway to help clear persistent viral reservoirs, more well-designed clinical trials are desperately needed to help the millions suffering from long COVID return to normal life.”

SARS-CoV-2 peptide fragments can reassemble with dsRNA into proinflammatory complexes, amplifying immune responses.

These complexes trigger cytokine secretion in various cell types, mimicking severe COVID-19 inflammation.

“Here is the first randomized trial to show that an antiviral can prevent Long Covid.

In the PANORAMIC trial, people randomized to molnupiravir had less risk of Long Covid than people who received no antivirals

My comment in the link below. A short🧵”

Literally living WITH Covid.

The use of antivirals to reduce the risk of long COVID is grounded in the hypothesis that viral persistence and possible ongoing replication of SARS-CoV-2 are major mechanistic pathways responsible for long COVID

ANTIVIRAL THERAPIES FOR PERSISTENT COVID/LONG COVID 83% SUCCESS 70 of 84 cases with the aggravating factor of immunosuppression

The types of treatment were grouped into: Prolonged Antiviral therapy Combination Antivirals Mixed therapy: Antiviral +Antibody